

UNCLASSIFIED

Exhibit R-2, RDT&E Budget Item Justification: PB 2016 Navy	Date: February 2015
---	----------------------------

Appropriation/Budget Activity 1319: <i>Research, Development, Test & Evaluation, Navy / BA 5: System Development & Demonstration (SDD)</i>	R-1 Program Element (Number/Name) PE 0604771N / <i>Medical Development</i>
--	--

COST (\$ in Millions)	Prior Years	FY 2014	FY 2015	FY 2016 Base	FY 2016 OCO	FY 2016 Total	FY 2017	FY 2018	FY 2019	FY 2020	Cost To Complete	Total Cost
Total Program Element	88.987	27.725	27.287	9.443	-	9.443	9.599	9.365	9.609	9.805	Continuing	Continuing
0933: <i>Medical/Dental Equipment Dev</i>	25.211	8.725	8.287	9.443	-	9.443	9.599	9.365	9.609	9.805	Continuing	Continuing
9999: <i>Congressional Adds</i>	63.776	19.000	19.000	-	-	-	-	-	-	-	-	101.776

A. Mission Description and Budget Item Justification

The purpose of this budget item is to develop biomedical equipment and related techniques to reduce morbidity; to enhance the logistic feasibility of modern medical care for combat casualties; to sustain casualties for evacuation to fixed medical facilities for definitive care; and to ensure that personnel are medically qualified for military duty. There is a strong potential for dual use, technology transfer, and biotechnology firms/industry participation in the projects.

B. Program Change Summary (\$ in Millions)	FY 2014	FY 2015	FY 2016 Base	FY 2016 OCO	FY 2016 Total
Previous President's Budget	28.458	8.287	9.935	-	9.935
Current President's Budget	27.725	27.287	9.443	-	9.443
Total Adjustments	-0.733	19.000	-0.492	-	-0.492
• Congressional General Reductions	-	-			
• Congressional Directed Reductions	-	-			
• Congressional Rescissions	-	-			
• Congressional Adds	-	19.000			
• Congressional Directed Transfers	-	-			
• Reprogrammings	-	-			
• SBIR/STTR Transfer	-0.732	-			
• Program Adjustments	-	-	-0.500	-	-0.500
• Rate/Misc Adjustments	-0.001	-	0.008	-	0.008

Congressional Add Details (\$ in Millions, and Includes General Reductions)

Project: 9999: *Congressional Adds*

Congressional Add: *Military Dental Research*

Congressional Add: *Wound Care Research (transferred from Defense Health Program)*

Congressional Add Subtotals for Project: 9999

Congressional Add Totals for all Projects

FY 2014	FY 2015
6.000	6.000
13.000	13.000
19.000	19.000
19.000	19.000

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2016 Navy									Date: February 2015			
Appropriation/Budget Activity 1319 / 5					R-1 Program Element (Number/Name) PE 0604771N / Medical Development				Project (Number/Name) 0933 / Medical/Dental Equipment Dev			
COST (\$ in Millions)	Prior Years	FY 2014	FY 2015	FY 2016 Base	FY 2016 OCO	FY 2016 Total	FY 2017	FY 2018	FY 2019	FY 2020	Cost To Complete	Total Cost
0933: Medical/Dental Equipment Dev	25.211	8.725	8.287	9.443	-	9.443	9.599	9.365	9.609	9.805	Continuing	Continuing
Quantity of RDT&E Articles		-	-	-	-	-	-	-	-	-		
A. Mission Description and Budget Item Justification												
The purpose of this budget item is to develop biomedical equipment and related techniques to reduce morbidity; to enhance the logistic feasibility of modern medical care for combat casualties; to sustain casualties for evacuation to fixed medical facilities for definitive care; and to ensure that personnel are medically qualified for military duty. Each work unit undertaken in this project has a military requirement. Efforts are justified based upon military payoff and cost benefit. There is a strong potential for dual use, technology transfer, and biotechnology firms/industry participation in the projects.												
B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)								FY 2014	FY 2015	FY 2016 Base	FY 2016 OCO	FY 2016 Total
Title: Medical/Dental Equipment Dev								8.725	8.287	9.443	-	9.443
								Articles:				
FY 2014 Accomplishments: -Continued to augment efforts with the ongoing clinical trial effort to test, for safety and efficacy, a militarily relevant malaria vaccine regimen utilizing a promising vaccine candidate. -Continued integration of a centralized bio-surveillance repository for open and DoD health surveillance data to provide a more robust picture of overall threats in an area. -Continued to validate the efficacy and pharmacodynamics of intranasal scopolamine for the prevention of motion sickness in dynamic military environments. -Continued to integrate efforts in wound closure, improvement of diagnostic measures, and development of an Osseo-integration device. -Continued joint development projects with MARCORSYSCOM acquisition including developing Mobile Oxygen Ventilation and External Suction (MOVES) SLC development and improved ruggedization based on prior years test and evaluation results. This device is a pre-planned product improvement for FRSS deployment for Military Treatment Facilities, Medicine Clinics, Corpsman, and Navy or USMC Special Operations. -Continued USMC Marine Resiliency study including assessment of longitudinal data, including pre-deployment, post-intervention efforts, and blast exposure measurements that may be used to predict risk and resilience. -Continued validation of an alternative watchstanding schedule on Naval Surface Combatants in support of an individualized fatigue-mitigated scheduling. -Continued fleet usability testing and validation for the Individual Fatigue -Based Scheduling and Countermeasure System that predicts, prevents, detects, and mitigates periods of high risk associated with												

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2016 Navy			Date: February 2015			
Appropriation/Budget Activity 1319 / 5		R-1 Program Element (Number/Name) PE 0604771N / Medical Development		Project (Number/Name) 0933 / Medical/Dental Equipment Dev		
B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)		FY 2014	FY 2015	FY 2016 Base	FY 2016 OCO	FY 2016 Total
fatigue. Individualized performance risk will be predicted and prevented by providing individual fatigue optimized schedules and mitigation strategies. -Completed USMC suicide prevention related efforts including post-mortem investigative procedure to reconstruct the life-style and circumstances in an effort to predict suicide risk. -Completed validation of computer color vision test for use in Naval Aviation that isolates and classifies red-green and yellow-blue color deficiencies. -Completed efforts to evaluate validate effectiveness of pharmaceuticals in the treatment of heterotopic ossification. -Initiated a challenge model to evaluate the efficacy in preventing Campylobacteriosis in subjects challenged with Campylobacter jejuni. -Initiated efforts to validate a mobile EEG device viable for objective assessment of brain function. -Initiated effort to validate assessment metrics for the submarine based team behaviors tool. -Initiated transition projects from the Force Health Protection Future Naval Capability Program. This is a continued effort toward initiating Development, Testing, and Evaluation program for transition products from the Office of Naval Research 6.3 Advanced Development program. Focus is on transition of and the mitigation of neurotrauma. -Initiated Naval Expeditionary Health Service Support Phase 1: Shore based capabilities based military treatment facility. FY 2015 Plans: -Continue to augment efforts with the ongoing clinical trial effort to test, for safety and efficacy, a militarily relevant malaria vaccine regimen utilizing a promising vaccine candidate. -Continue integration of a centralized bio-surveillance repository for open and DoD health surveillance data to provide a more robust picture of overall threats in an area. -Continue to validate the efficacy and pharmacodynamics of intranasal scopolamine for the prevention of motion sickness in dynamic military environments. -Continue joint development projects with MARCORSYSCOM acquisition including developing Mobile Oxygen Ventilation and External Suction (MOVES) SLC development and to include new test and evaluation following improved ruggedization. This device is a pre-planned product improvement for FRSS deployment for MTFs, Medicine Clinics, Corpsman, and Navy or USMC Special Operations. -Continue fatigue mitigation and validation of scheduling tools to include validation of an alternative watchstanding schedule on Naval Surface Combatants in support of an individualized fatigue-mitigated scheduling.						

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2016 Navy			Date: February 2015			
Appropriation/Budget Activity 1319 / 5		R-1 Program Element (Number/Name) PE 0604771N / Medical Development		Project (Number/Name) 0933 / Medical/Dental Equipment Dev		
B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)		FY 2014	FY 2015	FY 2016 Base	FY 2016 OCO	FY 2016 Total
-Continue utilization validation of Individual Fatigue -Based Scheduling and Countermeasure System that predicts, prevents, detects, and mitigates periods of high risk associated with fatigue. Individualized performance risk will be predicted and prevented by providing individual fatigue optimized schedules and mitigation strategies. -Continue clinical trials to evaluate the efficacy in preventing Campylobacteriosis in subjects challenged with Campylobacter jejuni. -Continue efforts to validate a mobile EEG device viable for objective assessment of brain function. -Continue effort to validate assessment metrics for the submarine based team behaviors tool. -Continued transition projects from the Force Health Protection Future Naval Capability Program. This is a continued effort toward initiating Development, Testing, and Evaluation program for transition products from the Office of Naval Research 6.3 Advanced Development program. Focus of transition is initiation of low volume resuscitation agents and the continuation of mitigation of neurotrauma. -Continue Naval Expeditionary Health Service Support Phase 1: Shore based capabilities based military treatment facility. -Complete USMC Marine Resiliency study including assessment of longitudinal data, including pre-deployment, post-intervention efforts, and blast exposure measurements that may be used to predict risk and resilience. -Complete integration of efforts in wound closure, improvement of diagnostic measures, development of an Osseo-integration device. FY 2016 Base Plans: -Continue to augment efforts with the ongoing clinical trial effort to test, for safety and efficacy, a militarily relevant malaria vaccine regimen utilizing a promising vaccine candidate. -Continue fatigue mitigation and validation of scheduling tools. -Continue joint development projects with MARCORSYSCOM acquisition for medical products and equipment, including initiating validation patient warming device and psychological tools associated with forward care. - Continue and initiate transition projects from the Force Health Protection Future Naval Capability Program. This is a continued effort toward initiating Development, Testing, and Evaluation program for transition products from the Office of Naval Research 6.3 Advanced Development program. -Continue Naval Expeditionary Health Service Support: Initiate ship based capabilities based military treatment facility. -Complete integration of a centralized bio-surveillance repository for open and DoD health surveillance data to provide a more robust picture of overall threats in an area.						

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2016 Navy			Date: February 2015		
Appropriation/Budget Activity 1319 / 5		R-1 Program Element (Number/Name) PE 0604771N / <i>Medical Development</i>		Project (Number/Name) 0933 / <i>Medical/Dental Equipment Dev</i>	
B. Accomplishments/Planned Programs (\$ in Millions, Article Quantities in Each)		FY 2014	FY 2015	FY 2016 Base	FY 2016 OCO
-Complete validation of the efficacy and pharmacodynamics of intranasal scopolamine for the prevention of motion sickness in dynamic military environments. FY 2016 OCO Plans: N/A					
Accomplishments/Planned Programs Subtotals		8.725	8.287	9.443	-
C. Other Program Funding Summary (\$ in Millions) N/A					
Remarks					
D. Acquisition Strategy					
-The acquisition strategy for product lines and products in the Medical Development Program is designed and implemented consistent with the particular product and with the nature and size of the investment. -The Medical Development Program operates with a Memorandum of Understanding with the Marine Corps Systems Command (Family of Field Medical Equipment) for co-development of products for procurement by the USMC. The acquisition strategy for these products involved direct partnership with the acquisition and procurement professionals at Marine Corps Systems Command. The program's major Product Areas in the Medical Development Program are: 1) Equipment, 2) Pharmaceuticals/Biologics, and 3) Knowledge/Concepts. The primary Program Areas of Interest are in: 1) Expeditionary Medicine (Navy in Terrestrial, Maritime Surface, Submarine, & Aviation Operations), USMC in Expeditionary Operations. In these areas the focus is on Levels I and II in Clinical Care Medicine; and 2) Products developed for battlefield treatment of Combat Casualties & Combat Trauma, focusing on delivery of Levels III and IV of care. -For areas 1 and 2, there are two primary acquisition strategies. The first is to test and evaluate commercially-developed medical product candidates in managed trials for ultimate Food and Drug Administration (FDA) approval. Partnerships with commercial developers ensure that products of military interest are available for procurement across the DoD, Federal Government, and commercial market. During development, DoD end users are included in the process to the extent possible. The second strategy is to drive the development process with DoD program investments. This process involves developing in-house or industrial prototypes in government-managed programs to meet military and regulatory requirements for production and fielding. -Both strategies promote advanced preparation of procurement plans in line with the product availability. Major Medical Development programs falling in these categories are: MOVES and MOVES anesthesia module (Equipment), Dengue vaccine, and Infusible Haemostatic-Phase I Clinical Trials (Pharmaceuticals/Biologics). -The Third Product Area (Knowledge/Concepts) is focused on the introduction of technologies, techniques, and procedures that alter medical practice and standards of care. These primarily require early involvement of the senior leadership of military medicine, in that the result of the program is modification of concepts of operations, policy, and/or doctrine. These are often much smaller; Medical Development Program examples include Navy/USMC Medical Planning Requirement Assessment and Crisis Action Planning Tool Transition.					

UNCLASSIFIED

PE 0604771N: *Medical Development*
Navy

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2016 Navy												Date: February 2015			
Appropriation/Budget Activity 1319 / 5						R-1 Program Element (Number/Name) PE 0604771N / Medical Development				Project (Number/Name) 0933 / Medical/Dental Equipment Dev					
Product Development (\$ in Millions)				FY 2014		FY 2015		FY 2016 Base		FY 2016 OCO		FY 2016 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Product Development: Malaria Vaccine	Allot	Naval Medical Research Center : Silver Spring, MD	4.552	0.304	Dec 2013	0.850	Mar 2015	1.000	Mar 2016	-		1.000	-	6.706	-
Individualized Fatigue Base Scheduling	SS/FP	Pulsar Informatics : Philadelphia, PA	4.060	0.883	Jan 2014	-		-		-		-	-	4.943	-
Product Development USMC Resiliency Study II	SS/FP	HQ USMC: University of San Diego, CA : San Diego, CA	6.798	0.743	Apr 2014	-		-		-		-	-	7.541	-
Product Development: USMC Suicide Prevention Program	MIPR	HQ USMC VA : San Diego, CA	1.828	-		-		-		-		-	-	1.828	-
Product Development: Mobile Oxygenation Ventilation and External Suction - SLC	C/FFP	Thornhill Research Inc. : Toronto, Canada	0.840	1.915	Aug 2014	-		-		-		-	-	2.755	-
Product Development: Post Traumatic Stress Mitigation, No Product/ Contract Greater than \$1M individually	Various	Various : Various	0.948	0.429	Dec 2013	2.012	Jun 2015	2.105	Mar 2016	-		2.105	Continuing	Continuing	Continuing
Product Development: Preventive Medicine No Product/Contract Greater than \$1M Individually	Various	Various : Various	3.020	1.919	Jan 2014	1.606	Jun 2015	2.134	Mar 2016	-		2.134	Continuing	Continuing	Continuing
Product Development: Undersea Medicine: No Product/Contract Greater Than \$1M Individually	Various	Various : Various	0.265	0.198	Jan 2014	0.364	Jan 2015	0.768	Dec 2015	-		0.768	Continuing	Continuing	Continuing
Product Development: First Responder, Enroute Care and Hemmorhage Control. No Product/ Contract Greater Than \$1M Individually	Various	Various : Various	2.190	1.100	Jun 2014	2.102	Jun 2015	2.145	May 2016	-		2.145	Continuing	Continuing	Continuing

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2016 Navy												Date: February 2015			
Appropriation/Budget Activity 1319 / 5						R-1 Program Element (Number/Name) PE 0604771N / Medical Development				Project (Number/Name) 0933 / Medical/Dental Equipment Dev					
Product Development (\$ in Millions)				FY 2014		FY 2015		FY 2016 Base		FY 2016 OCO		FY 2016 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Product Development: Wound Management, No Product/Contract Greater than \$!M Individually	Various	Various : Various	0.563	0.898	May 2014	0.973	Mar 2015	0.759	Jun 2016	-		0.759	Continuing	Continuing	Continuing
Subtotal			25.064	8.389		7.907		8.911		-		8.911	-	-	-
Support (\$ in Millions)				FY 2014		FY 2015		FY 2016 Base		FY 2016 OCO		FY 2016 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Program Support	Various	Various : Various	0.147	0.336	Aug 2014	0.380	Aug 2015	0.532	Aug 2016	-		0.532	Continuing	Continuing	Continuing
Subtotal			0.147	0.336		0.380		0.532		-		0.532	-	-	-
			Prior Years	FY 2014		FY 2015		FY 2016 Base		FY 2016 OCO		FY 2016 Total	Cost To Complete	Total Cost	Target Value of Contract
Project Cost Totals			25.211	8.725		8.287		9.443		-		9.443	-	-	-
Remarks															

UNCLASSIFIED

Exhibit R-4, RDT&E Schedule Profile: PB 2016 Navy																							Date: February 2015						
Appropriation/Budget Activity 1319 / 5												R-1 Program Element (Number/Name) PE 0604771N / Medical Development												Project (Number/Name) 0933 / Medical/Dental Equipment Dev					
Preventive Medicine: Malaria Vaccine (Partner Leveraged)	FY 2014				FY 2015				FY 2016				FY 2017				FY 2018				FY 2019				FY 2020				
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	
Stage 2 Trials					Demonstration																								
Large Scale Efficacy/Safety Trials										Demonstration																			
FDA Biological License/Application																			Milestone										
2016DON - 0604771N - 0933																													

UNCLASSIFIED

Exhibit R-4, RDT&E Schedule Profile: PB 2016 Navy											Date: February 2015																			
Appropriation/Budget Activity 1319 / 5											R-1 Program Element (Number/Name) PE 0604771N / Medical Development										Project (Number/Name) 0933 / Medical/Dental Equipment Dev									
Psychological Health/Fatigue: Individualized Fatigue Based Scheduling and Countermeasure System (IFBCS)	FY 2014				FY 2015				FY 2016				FY 2017				FY 2018				FY 2019				FY 2020					
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q		
Demonstrate Tailoring of Tool for Submarine Use			Demonstration ▼																											
User Testing						Milestone ▲																								
2016DON - 0604771N - 0933																														

UNCLASSIFIED

PE 0604771N: *Medical Development*
Navy

R-1 Line #133

Appropriation/Budget Activity 1319 / 5										R-1 Program Element (Number/Name) PE 0604771N / Medical Development										Project (Number/Name) 0933 / Medical/Dental Equipment Dev									
Psychological/Health/Fatigue: Marine Resiliency Study	FY 2014				FY 2015				FY 2016				FY 2017				FY 2018				FY 2019				FY 2020				
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	
Complete final data collection			Milestone ▲																										
2016DON - 0604771N - 0933																													

UNCLASSIFIED

Exhibit R-4, RDT&E Schedule Profile: PB 2016 Navy **Date:** February 2015

Appropriation/Budget Activity 1319 / 5	R-1 Program Element (Number/Name) PE 0604771N / <i>Medical Development</i>	Project (Number/Name) 0933 / <i>Medical/Dental Equipment Dev</i>
--	--	--

Expeditionary Medicine: MOVES SLC	FY 2014				FY 2015				FY 2016				FY 2017				FY 2018				FY 2019				FY 2020			
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4Q
Development of Ruggedized Mobile Oxygen, Ventilation, and External Suction (MOVES) System			▲																									
User testing of Ruggedized Mobile Oxygen, Ventilation, and External Suction (MOVES) System							▲																					

2016DON - 0604771N - 0933

UNCLASSIFIED

PE 0604771N: *Medical Development*
Navy

R-1 Line #133

Project (Number/Name)	0933 / Medical/Dental Equipment Dev
------------------------------	-------------------------------------

[illegible]

2016DON - 0604771N - 0933

UNCLASSIFIED

PE 0604771N: *Medical Development*
Navy

R-1 Line #133

Project (Number/Name)
0933 / Medical/Dental Equipment Dev

[illegible]

2016DON - 0604771N - 0933

UNCLASSIFIED

Exhibit R-4A, RDT&E Schedule Details: PB 2016 Navy

Date: February 2015

Appropriation/Budget Activity

1319 / 5

R-1 Program Element (Number/Name)

PE 0604771N / Medical Development

Project (Number/Name)

0933 / Medical/Dental Equipment Dev

Schedule Details

Events by Sub Project	Start		End	
	Quarter	Year	Quarter	Year
<i>Preventive Medicine: Malaria Vaccine (Partner Leveraged)</i>				
Schedule Detail	1	2014	2	2020
Stage 2 Trials: Schedule Detail	1	2015	1	2015
Large Scale Efficacy/Safety Trials: Schedule Detail	2	2016	2	2016
FDA Biological License/Application: Schedule Detail	2	2018	2	2018
<i>Psychological Health/Fatigue: Individualized Fatigue Based Scheduling and Countermeasure System (IFBCS)</i>				
Schedule Detail	2	2014	2	2016
Demonstrate Tailoring of Tool for Submarine Use: Schedule Detail	3	2014	3	2014
User Testing: Schedule Detail	2	2015	2	2015
<i>Psychological Health/Fatigue: Marine Resiliency Study</i>				
Schedule Detail	2	2014	4	2015
Complete final data collection: Schedule Detail	3	2015	3	2015
<i>Expeditionary Medicine: MOVES SLC</i>				
Schedule Detail	3	2014	4	2016
Development of Ruggedized Mobile Oxygen, Ventilation, and External Suction (MOVES) System: Schedule Detail	3	2015	3	2015
User testing of Ruggedized Mobile Oxygen, Ventilation, and External Suction (MOVES) System: Schedule Detail	3	2016	3	2016
<i>Expeditionary Medicine: NEHSS CB MTF</i>				
Schedule Detail	3	2014	1	2018
<i>Force Health Protection Future Capability Program Transition Products</i>				
Schedule Detail	2	2014	2	2018

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2016 Navy										Date: February 2015		
Appropriation/Budget Activity 1319 / 5					R-1 Program Element (Number/Name) PE 0604771N / <i>Medical Development</i>				Project (Number/Name) 9999 / <i>Congressional Adds</i>			
COST (\$ in Millions)	Prior Years	FY 2014	FY 2015	FY 2016 Base	FY 2016 OCO	FY 2016 Total	FY 2017	FY 2018	FY 2019	FY 2020	Cost To Complete	Total Cost
9999: <i>Congressional Adds</i>	63.776	19.000	19.000	-	-	-	-	-	-	-	-	101.776
Quantity of RDT&E Articles		-	-	-	-	-	-	-	-	-		

Note
None

A. Mission Description and Budget Item Justification
Congressional Adds

<u>B. Accomplishments/Planned Programs (\$ in Millions)</u>	FY 2014	FY 2015
<i>Congressional Add:</i> Military Dental Research <i>FY 2014 Accomplishments:</i> All Dental Research efforts are underway for FY14. Research efforts include a number of efforts from FY13 including surveillance of cranio-facial injuries, combat dentistry, dental disease non-battle injuries and oral/facial disease in military personnel; evaluation of immune response association with maxillofacial bone regeneration. <i>FY 2015 Plans:</i> Continue efforts in cranio-facial injury surveillance; combat dentistry; treatment of maxillofacial injury; dental disease non-battle injuries; oral/facial disease and infection in military personnel.	6.000	6.000
<i>Congressional Add:</i> Wound Care Research (transferred from Defense Health Program) <i>FY 2014 Accomplishments:</i> Continue to develop novel diagnostics and treatments to enhance the care of the wounded warfighter. <i>FY 2015 Plans:</i> Continue to develop novel diagnostics and treatments to enhance the care of the wounded warfighter.	13.000	13.000
Congressional Adds Subtotals	19.000	19.000

C. Other Program Funding Summary (\$ in Millions)
N/A

Remarks

D. Acquisition Strategy
None

UNCLASSIFIED

Exhibit R-2A, RDT&E Project Justification: PB 2016 Navy		Date: February 2015
Appropriation/Budget Activity 1319 / 5	R-1 Program Element (Number/Name) PE 0604771N / Medical Development	Project (Number/Name) 9999 / Congressional Adds

E. Performance Metrics

Not required for Congressional adds.

UNCLASSIFIED

Exhibit R-3, RDT&E Project Cost Analysis: PB 2016 Navy													Date: February 2015		
Appropriation/Budget Activity 1319 / 5						R-1 Program Element (Number/Name) PE 0604771N / <i>Medical Development</i>				Project (Number/Name) 9999 / <i>Congressional Adds</i>					

Product Development (\$ in Millions)				FY 2014		FY 2015		FY 2016 Base		FY 2016 OCO		FY 2016 Total			
Cost Category Item	Contract Method & Type	Performing Activity & Location	Prior Years	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Award Date	Cost	Cost To Complete	Total Cost	Target Value of Contract
Congressional Add	C/BA	Not Specified : Not Specified	63.776	19.000	Aug 2014	19.000	Jul 2015	-		-		-	-	101.776	-
Subtotal			63.776	19.000		19.000		-		-		-	-	101.776	-

	Prior Years	FY 2014	FY 2015	FY 2016 Base		FY 2016 OCO		FY 2016 Total	Cost To Complete	Total Cost	Target Value of Contract
Project Cost Totals	63.776	19.000	19.000	-		-		-	-	101.776	-

Remarks

UNCLASSIFIED

Exhibit R-4, RDT&E Schedule Profile: PB 2016 Navy	Date: February 2015
--	----------------------------

Appropriation/Budget Activity 1319 / 5	R-1 Program Element (Number/Name) PE 0604771N / <i>Medical Development</i>	Project (Number/Name) 9999 / <i>Congressional Adds</i>
--	--	--

FY 2014				FY 2015				FY 2016				FY 2017				FY 2018				FY 2019				FY 2020			
1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4	1	2	3	4

Proj 9999	
Military Dental Research: Schedule Detail	
Wound Care Research: Schedule Detail	

UNCLASSIFIED

Exhibit R-4A, RDT&E Schedule Details: PB 2016 Navy	Date: February 2015
---	----------------------------

Appropriation/Budget Activity 1319 / 5	R-1 Program Element (Number/Name) PE 0604771N / <i>Medical Development</i>	Project (Number/Name) 9999 / <i>Congressional Adds</i>
--	--	--

Schedule Details

Events by Sub Project	Start		End	
	Quarter	Year	Quarter	Year
<i>Proj 9999</i>				
Military Dental Research: Schedule Detail	1	2014	4	2014
Wound Care Research: Schedule Detail	1	2014	4	2014